Skip to main content

A Phase 1 Trial of D2C7-IT in Combination with an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorai

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Exvade Bioscience Inc.

Start Date

June 11, 2024

End Date

May 31, 2027
 

Administered By

Duke Cancer Institute

Awarded By

Exvade Bioscience Inc.

Start Date

June 11, 2024

End Date

May 31, 2027